Confluence Wealth Services Inc. Increases Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Confluence Wealth Services Inc. boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 16.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 774 shares of the medical equipment provider’s stock after buying an additional 108 shares during the period. Confluence Wealth Services Inc.’s holdings in Intuitive Surgical were worth $344,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Indiana Trust & Investment Management CO grew its position in shares of Intuitive Surgical by 5.3% during the second quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after purchasing an additional 25 shares in the last quarter. Hoxton Planning & Management LLC grew its holdings in Intuitive Surgical by 4.9% during the 2nd quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after buying an additional 25 shares in the last quarter. First Affirmative Financial Network increased its stake in Intuitive Surgical by 2.7% in the 2nd quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock worth $443,000 after acquiring an additional 26 shares during the last quarter. Advance Capital Management Inc. raised its holdings in shares of Intuitive Surgical by 3.8% during the 1st quarter. Advance Capital Management Inc. now owns 740 shares of the medical equipment provider’s stock worth $295,000 after acquiring an additional 27 shares in the last quarter. Finally, Perigon Wealth Management LLC boosted its position in shares of Intuitive Surgical by 0.5% during the 1st quarter. Perigon Wealth Management LLC now owns 5,363 shares of the medical equipment provider’s stock valued at $2,140,000 after acquiring an additional 27 shares during the last quarter. 83.64% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the transaction, the senior vice president now owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the sale, the senior vice president now owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Robert Desantis sold 239 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $416.60, for a total value of $99,567.40. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,293,799.60. The disclosure for this sale can be found here. Insiders sold a total of 53,056 shares of company stock valued at $25,276,044 over the last three months. 0.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages recently weighed in on ISRG. Robert W. Baird boosted their price target on shares of Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research report on Friday, July 19th. Citigroup boosted their target price on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Evercore ISI lowered their price target on shares of Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a report on Friday, July 19th. Morgan Stanley boosted their price objective on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Finally, Barclays raised their price objective on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research note on Thursday, July 18th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $446.45.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $492.63 on Monday. The company has a market capitalization of $175.06 billion, a PE ratio of 88.92, a P/E/G ratio of 5.43 and a beta of 1.39. The company has a 50 day moving average price of $454.69 and a 200-day moving average price of $414.94. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $493.97.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same period in the previous year, the company posted $1.18 EPS. Intuitive Surgical’s revenue was up 14.5% on a year-over-year basis. On average, analysts forecast that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.